The Dutch life science sector is amongst the world’s best. To stay ahead of the competition, forming the right alliances is essential. Our lawyers and civil-law notaries are frequently asked to execute and supervise transactions and to perform due diligence projects. The M&A members of our life sciences team assist in negotiating and structuring acquisitions and various forms of cooperation. In the sector, short and mid-term capital requirements remain a constant challenge. We are very experienced in assisting in venture capital, private equity, MBO and MBI transactions, the setting up of joint ventures and financing agreements.
Because of the very significant interests involved, the distribution of patented medicines often leads to proceedings regarding the infringement and invalidity of patents and SPCs, advertising disputes as well as regulatory proceedings pertaining to marketing authorisations. Members of our life sciences team have been involved in many of such proceedings, e.g. regarding Fosamax (alendronate), Losec and Nexium (omeprazole and esomeprazole), Lexapro (escitalopram), Exelon (rivastigmine) and Aclasta (zoledronate). Also in the field of medical devices such as EEG devices, balloon catheter stents, heart-lung machines and breast implants, we help to resolve IP disputes between manufacturers as well as product liability and mass damages claims. Besides dispute resolution, we assist companies in the life sciences sector in drafting and reviewing licences, distribution agreements and R&D agreements.
On a pro bono basis we provide our IP expertise for the development of a portable artificial kidney, a project of the Dutch Neokidney Foundation.
Read more about Pharma & regulatory
‘They have deep knowledge of the corporate structure of a business, so they can easily manoeuvre themselves where necessary’. – Legal 500, 2022
‘The depth of experience makes this practice unique’. – Legal 500, 2022
‘It’s great to work with lawyers who not only have top legal insight and knowledge, but also a genuinely commercial approach’. – Legal 500, 2021